ArticleCNS oncology2018
Distribution of tumor-infiltrating immune cells in glioblastoma.
Article in CNS oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 65 citations in OpenAlex.
- Rapid immunohistochemistry for intraoperative differentiation between high-grade gliomas and primary central nervous system lymphomas: a multicenter prospective study.Brain tumor pathology · 2026Article
- Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry.Journal of neuro-oncology · 2026Review
- Article
- Mapping kinase-dependent tumor immune adaptation with multiplexed single-cell CRISPR screens.bioRxiv : the preprint server for biology · 2026Article
- Influence of the Cholinergic System on the Pathogenesis of Glioblastoma: Impact of the Neutrophil Granulocytes.International journal of molecular sciences · 2025Article
- Tumor and immune cell distribution in the tumor core and outer part of glioblastoma, IDH wildtype.Journal of neuro-oncology · 2025Article
- Ferroptosis Enhances T Lymphocyte Infiltration into Glioblastoma Spheroids.Antioxidants (Basel, Switzerland) · 2025Article
- Unraveling Glioblastoma Heterogeneity: Advancing Immunological Insights and Therapeutic Innovations.Brain sciences · 2025Review
- 5-ALA Assisted Surgery of Human Glioblastoma Samples Reveals an Enrichment of T Cells Expressing PD-1 and CD103 in the Intermediate and Marginal Layers.European journal of immunology · 2025Article
- Tumor cell-derived spermidine promotes a protumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition.The Journal of clinical investigation · 2024Article
- Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study.Cancers · 2024Article
- Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.Journal for immunotherapy of cancer · 2024Article
- Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.Frontiers in immunology · 2024Review
- Systemic and local immunosuppression in glioblastoma and its prognostic significance.Frontiers in immunology · 2024Review
- Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy.Biology · 2023Review
- Development of a human glioblastoma model using humanized DRAG mice for immunotherapy.Antibody therapeutics · 2023Article
- Development and validation of cuproptosis molecular subtype-related signature for predicting immune prognostic characterization in gliomas.Journal of cancer research and clinical oncology · 2023Article
- Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.Journal of neuro-oncology · 2023Article
- The strange Microenvironment of Glioblastoma.Revue neurologique · 2023Review
- Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment.Cellular and molecular neurobiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimEvaluation of features related to infiltrating immune cell level in glioblastoma.
methodsTumor-infiltrating lymphocytes (TILs) through H&E staining, and TILs (CD3, CD4, CD8 and CD20) and macrophage (CD68 and CD163) levels through immunohistochemistry were evaluated through digital analysis.
resultsCD68 (9.1%), CD163 (2.2%), CD3 (1.6%) and CD8 (1.6%) had the highest density. Higher CD4
conclusionMacrophages are more frequent than TILs. Some subsets are associated with clinical features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.